Lead Sponsor

University of Miami

Collaborators

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•1. Patients with persistent unresectable Gestational Trophoblastic Neoplasia (GTN) disease
•2. Female patients \>18 years old.
•3. Pretreatment archival tissue (if available) must be submitted for correlative studies. If pre-treatment tissue is not available, this does not exclude the patient.
•4. Patients must have recovered from the effects of recent surgery or radiotherapy (persistent toxicity, CTCAE grade ≤1 except for alopecia, sensory neuropathy, or fatigue).

•1. Prior therapy with anti-Programed Death (PD)1/Programed Death Ligand-1 (PD-L1) or anti-CTLA4 antibody
•2. Participant must not be simultaneously enrolled in any interventional clinical trial.
•3. Participant must not have had major surgery ≤3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects.
•4. Participant must not have received investigational therapy ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.

Related studies

NCT05139095 · Gestational Trophoblastic Neoplasia

NCT06169644 · Gestational Trophoblastic Neoplasia

NCT05635344 · Gestational Trophoblastic Disease, Gestational Trophoblastic Neoplasia, and more

NCT03135769 · Gestational Trophoblastic Neoplasias (GTN)

NCT06900699 · Gestational Trophoblastic Neoplasias (GTN)

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia